NTC grants to Zhaoke exclusive license and distribution rights in Asia for NTC014, innovative drug for bacterial conjunctivitis

  • Jan 14, 2021

NTC, an international R&D focused pharmaceutical company headquartered in Italy, and Zhaoke (Hong Kong) Ophthalmology Pharmaceuticals Limited, having a fully integrated ophthalmic platform with strong foundation in eyecare, announce today their agreement for exclusive license and distribution rights of NTC014, innovative fixed combination of a quinolone antibiotic and a NSAID in eye drops.

New CE certifications for three NTC products based on tiab technology

  • Jul 22, 2020

NTC Srl, R&D focused pharmaceutical company headquartered in Italy, has obtained CE certifications for three medical devices based on TIAB technology: a new vaginal gel GENIGEL, a proctological cream-gel TIAHEM and a powder for wound care TIAHEL.

NTC grants license and distribution rights in Israel to Taro Pharmaceutical Industries

  • Jun 17, 2020

NTC Srl, an R&D focused pharmaceutical company headquartered in Italy, has granted exclusive license and distribution rights to one of its research and development products, a fixed combination in eye drops, in Israel to Taro Pharmaceutical Industries (”Taro”), a research-based international pharmaceutical company.

NTC for Covid-19 emergency: our commitment is playing an active role to support community and raising awareness

  • Apr 30, 2020

The  Covid-19 situation has been evolving: the responsibility of everyone in implementing some essential measures, such as social distancing, personal hygiene and the use of protective equipment is fundamental to prevent Covid-19’s outbreak and approach safely our future social life.